Hive Digital’s Stock Is Downgraded Ahead of Earnings

15 hours ago 5

CryptoProwl

Fri, August 14, 2026 astatine 9:26 AM CDT 1 min read

Hive Digital's Stock Is Downgraded Ahead of Earnings

Hive Digital's Stock Is Downgraded Ahead of Earnings

The banal of Canada's Hive Digital Technologies (NASDAQ: $HIVE) has received a downgrade hours earlier the information centre relation is owed to merchandise its latest fiscal results. 

Wall Street concern slope Keefe Bruyette has trimmed its terms people connected Hive Digital's banal to $4.50 U.S. from $5.00 U.S. previously. 

The caller terms people is 73% higher than wherever the banal presently trades. Keefe Bruyette besides placed a hold-equivalent "market perform" standing connected HIVE stock.

More From Cryptoprowl:

  • MEXC Report: 74.2% of Traditional Finance Users Have Shifted Their Trading Activity to Crypto Exchanges

  • MEXC July TradFi Trading Shifts Toward AI Storage arsenic SNDK Futures Volume Surges More Than 15x Times

  • Polymarket Hires Former Uber Executive To Lead Growth Initiative

  • Hyperliquid Turns to CFTC for Path Into U.S. Perpetual Futures Market

  • Canadian Defense Tech Firm Jumps 92% arsenic Government Revenue Boosts Margins

The steadfast cites wide optimism for high-performance computing (HPC) and colocation request with artificial quality (A.I.) information centres that Hive Digital operates.

However, analysts astatine Keefe Bruyette besides explicit caution astir backing risks and A.I.-tenant exemplary hazard successful assessing Hive Digital's outlook.

The downgrade comes with Hive Digital scheduled to study its latest fiscal results aft markets adjacent connected Aug. 14. 

The downgrade besides comes aft Hive Digital precocious delayed filing its 10-Q quarterly study with the U.S. Securities and Exchange Commission (SEC).

A 10-Q is simply a study that each publically traded companies indispensable taxable to the SEC. It contains a company's unaudited fiscal statements. Hive Digital has asked the SEC for an extension. 

HIVE banal has declined 18% implicit the past period heading into the company's fiscal results. However, the company's stock terms has risen 16% implicit the past twelvemonth to commercialized astatine $2.62 U.S. 

Read Entire Article